These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37659201)

  • 21. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
    Yue L; Sharma V; Horvat NP; Akuffo AA; Beatty MS; Murdun C; Colin C; Billington JMR; Goodheart WE; Sahakian E; Zhang L; Powers JJ; Amin NE; Lambert-Showers QT; Darville LN; Pinilla-Ibarz J; Reuther GW; Wright KL; Conti C; Lee JY; Zheng X; Ng PY; Martin MW; Marshall CG; Koomen JM; Levine RL; Verma A; Grimes HL; Sotomayor EM; Shao Z; Epling-Burnette PK
    Blood; 2020 Jan; 135(3):191-207. PubMed ID: 31750881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].
    Yi Z; Wenwen L; Kun W; Jian S
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jul; 39(7):751-759. PubMed ID: 31340905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Garcinol Is an HDAC11 Inhibitor.
    Son SI; Su D; Ho TT; Lin H
    ACS Chem Biol; 2020 Nov; 15(11):2866-2871. PubMed ID: 33034447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.
    Gao L; Cueto MA; Asselbergs F; Atadja P
    J Biol Chem; 2002 Jul; 277(28):25748-55. PubMed ID: 11948178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285.
    Zhou Z; Zhong L; Chu X; Wan P; Dan W; Shao X; Chen S; Zhang Z; Lu Y; Liu B
    Med Oncol; 2023 Oct; 40(11):325. PubMed ID: 37805625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
    Tian Y; Lv W; Li X; Wang C; Wang D; Wang PG; Jin J; Shen J
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2943-2945. PubMed ID: 28501514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity-Guided Design of HDAC11-Specific Inhibitors.
    Son SI; Cao J; Zhu CL; Miller SP; Lin H
    ACS Chem Biol; 2019 Jul; 14(7):1393-1397. PubMed ID: 31264832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a novel histone deacetylase inhibitor unveils the role of HDAC11 in alleviating depression by inhibition of microglial activation.
    Baek SY; Lee J; Kim T; Lee H; Choi HS; Park H; Koh M; Kim E; Jung ME; Iliopoulos D; Lee JY; Kim J; Lee S
    Biomed Pharmacother; 2023 Oct; 166():115312. PubMed ID: 37567072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker.
    Li R; Wu X; Zhao P; Xue K; Li J
    FASEB J; 2022 Jul; 36(7):e22326. PubMed ID: 35657209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase 10, a potential epigenetic target for therapy.
    Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Niu Z; He W
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 33997894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDAC11, an emerging therapeutic target for metabolic disorders.
    Chen H; Xie C; Chen Q; Zhuang S
    Front Endocrinol (Lausanne); 2022; 13():989305. PubMed ID: 36339432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
    Collier CD; Getty PJ; Greenfield EM
    Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
    Thurn KT; Thomas S; Moore A; Munster PN
    Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of novel POLA1-HDAC11 dual inhibitors.
    Dallavalle S; Musso L; Cincinelli R; Darwiche N; Gervasoni S; Vistoli G; Guglielmi MB; La Porta I; Pizzulo M; Modica E; Prosperi F; Signorino G; Colelli F; Cardile F; Fucci A; D'Andrea EL; Riccio A; Pisano C
    Eur J Med Chem; 2022 Jan; 228():113971. PubMed ID: 34772529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11.
    Ho TT; Peng C; Seto E; Lin H
    ACS Chem Biol; 2023 Apr; 18(4):803-809. PubMed ID: 36977486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developmental expression of histone deacetylase 11 in the murine brain.
    Liu H; Hu Q; Kaufman A; D'Ercole AJ; Ye P
    J Neurosci Res; 2008 Feb; 86(3):537-43. PubMed ID: 17893925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
    Gryder BE; Sodji QH; Oyelere AK
    Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.